Schoenberg Mark 4

What Happened

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold a total of 7,373 shares in three open-market/private-sale transactions on February 3, 2026. The sales were: 1,844 shares at $19.69 ($36,308); 1,843 shares at $19.69 ($36,289); and 3,686 shares at $19.69 ($72,577), for aggregate proceeds of $145,174.
• These were sales (code S) executed to satisfy withholding tax obligations upon the settlement of restricted stock units, not discretionary investment purchases.

Key Details

• Transaction date: February 3, 2026; Filing date: February 4, 2026 (filed timely).
• Price per share: $19.69; Total proceeds: $145,174.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: F1 — shares sold to satisfy withholding tax obligations upon RSU settlement (tax withholding).
• Transaction type/code: S = Sale; the sale was for tax withholding rather than a market-timed disposition.

Context

• Sales to cover tax withholding on RSU settlements are routine and common for employees receiving equity awards; they do not necessarily indicate the insider’s view on the company's outlook.
• For retail investors, purchases by insiders can be stronger signals of confidence; in this case, the reported activity appears administrative (tax-related) rather than an opportunistic sale.